pinoxin: Treatment group will receive prophylactic skin administration of Pinoxin，which is kind of Skin Protective Agent.
Placebo: Treatment group will receive prophylactic skin administration of placebo
Study summary
The incidence of radiation-induced skin injury is high, and effective preventive measures are currently lacking. This study evaluates the role of the skin protective agent Pinoxin in preventing skin injury. Patients are randomly assigned into two prospective groups: treatment group and control group. In treatment group, patients will receive Pinoxin treatment. In control group，patients will receive placebo treatment. The rate of grade 2 or greater skin injury will be analyzed.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥ 18 years, regardless of gender.
2. Pathologically diagnosed with a malignant tumor.
3. Scheduled to receive long-course radiotherapy with a total dose of ≥50 Gy, in accordance with standard treatment guidelines.
4. No prior history of radiotherapy.
5. Has provided signed and dated informed consent, indicating that the patient has been informed of all relevant aspects of the study.
6. Patients who are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
1. History of dermatologic conditions (e.g., vitiligo, psoriasis, etc.) or collagen vascular diseases.
2. Planned hypofractionated radiotherapy regimen.
3. Recent use (e.g., within 3 months) of similar topical protective agents.
4. Known hypersensitivity to any related components or materials.
5. Immunodeficiency disorders.
6. Women who are pregnant or lactating.
7. Any other condition that, in the investigator's judgment, may compromise patient safety or protocol compliance. This includes severe concomitant illnesses (including psychiatric disorders) requiring active treatment, significant laboratory abnormalities, or significant social/familial factors.
Primary outcome measure(s)
adverse effect — from the start of radiotherapy to 3 months Incidence of acute skin injury of Grade 2 or higher
≥ grade 2 acute skin injury — from the start of radiotherapy to 3 months Incidence of acute skin injury of Grade 2 or higher
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.